Distinguished in Meckel's Diverticulum

Jie G. Wu

State Key Laboratory Of Kidney Diseases, 
Beijing, CN 
Distinguished in Meckel's Diverticulum
State Key Laboratory Of Kidney Diseases, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Jie Wu practices in Beijing, China. Wu is rated as a Distinguished expert by MediFind in the treatment of Meckel's Diverticulum. Their top areas of expertise are Meckel's Diverticulum, IgA Nephropathy, Glomerulonephritis, Endoscopy, and Tissue Biopsy.

Their clinical research consists of co-authoring 446 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Meckel's Diverticulum.

Locations

State Key Laboratory Of Kidney Diseases, Beijing, China
Other Locations
Zhongshan Road 321, Nanjing, 210008, China
516 Jungong Rd, Shanghai, 200093, China
81 Meishan Road, Hefei, 230032, China
28 Fuxing Road, Beijing, 100083, China
State Key Laboratory Of Biochemical Engineering Institute Of Process Engineering Chinese Academy Of Sciences 1 North 2nd Street, Haidian, 100190, China
No. 399 WanYuan Road, Shanghai, 201102, China
168 Changhai Road, Shanghai, 200438, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3

446 Total Publications

FuXi-ENS: A machine learning model for efficient and accurate ensemble weather prediction.
FuXi-ENS: A machine learning model for efficient and accurate ensemble weather prediction.
Journal: Science advances
Published: October 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wu's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 79 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile